Clinical Trial Update: Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study [Phase 2]

View source ↗

Summary

This clinical trial entry describes a Phase 2 single-arm exploratory study of combining Ivarmacitinib, camrelizumab, and apatinib in unresectable advanced hepat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• Ivarmacitinib

Snippet

Sponsor: First Affiliated Hospital of Chongqing Medical University | Conditions: Hepatocellular Carcinomas, Resistance to Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING